VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Stock Comparison
DexCom, Inc. vs Novo Nordisk A/S
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
DexCom, Inc.
DXCM · Nasdaq Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into DexCom, Inc.'s moat claims, evidence, and risks.
View DXCM analysisNovo Nordisk A/S
NOVOB · Nasdaq Copenhagen
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.
View NOVOB analysisComparison highlights
- Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 82 / 100 for DexCom, Inc.).
- Segment focus: DexCom, Inc. has 1 segment (100% in Continuous glucose monitoring systems); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
- Moat breadth: DexCom, Inc. has 5 moat types across 3 domains; Novo Nordisk A/S has 5 across 3.
Primary market context
DexCom, Inc.
Continuous glucose monitoring systems
Global continuous glucose monitoring systems and glucose biosensing devices
Global, with FY2025 revenue 71.5% United States and 28.5% international
People with diabetes, metabolic-health users, caregivers, clinicians, payors, distributors and pharmacy channels
CGM device manufacturer, disposable sensor supplier, software/data platform and distribution partner
100%
Novo Nordisk A/S
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Global
Payers/providers and patients (via wholesalers/pharmacies/hospitals)
Originator pharma (R&D, regulatory, manufacturing, commercialization)
71.1%
Side-by-side metrics
Moat coverage
Shared moat types
DexCom, Inc. strengths
Novo Nordisk A/S strengths
Segment mix
DexCom, Inc. segments
Full profile >Continuous glucose monitoring systems
Oligopoly
Novo Nordisk A/S segments
Full profile >Diabetes care
Oligopoly
Obesity care
Duopoly
Rare disease
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.